172 related articles for article (PubMed ID: 30763133)
1. Multitarget-directed ligands for neurodegenerative diseases: real opportunity or blurry mirage?
Benchekroun M; Maramai S
Future Med Chem; 2019 Feb; 11(4):261-263. PubMed ID: 30763133
[No Abstract] [Full Text] [Related]
2. Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration.
Ramos E; Egea J; de Los Ríos C; Marco-Contelles J; Romero A
Future Med Chem; 2017 May; 9(8):765-780. PubMed ID: 28498717
[TBL] [Abstract][Full Text] [Related]
3. The emergence of designed multiple ligands for neurodegenerative disorders.
Geldenhuys WJ; Youdim MB; Carroll RT; Van der Schyf CJ
Prog Neurobiol; 2011 Sep; 94(4):347-59. PubMed ID: 21536094
[TBL] [Abstract][Full Text] [Related]
4. Multitarget Therapeutics for Neurodegenerative Diseases.
Gabr MT; Yahiaoui S
Biomed Res Int; 2020; 2020():6532827. PubMed ID: 32695817
[No Abstract] [Full Text] [Related]
5. Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases.
Gontijo VS; Viegas FPD; Ortiz CJC; de Freitas Silva M; Damasio CM; Rosa MC; Campos TG; Couto DS; Tranches Dias KS; Viegas C
Curr Neuropharmacol; 2020; 18(5):348-407. PubMed ID: 31631821
[TBL] [Abstract][Full Text] [Related]
6. Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H
Bautista-Aguilera ÓM; Hagenow S; Palomino-Antolin A; Farré-Alins V; Ismaili L; Joffrin PL; Jimeno ML; Soukup O; Janočková J; Kalinowsky L; Proschak E; Iriepa I; Moraleda I; Schwed JS; Romero Martínez A; López-Muñoz F; Chioua M; Egea J; Ramsay RR; Marco-Contelles J; Stark H
Angew Chem Int Ed Engl; 2017 Oct; 56(41):12765-12769. PubMed ID: 28861918
[TBL] [Abstract][Full Text] [Related]
7. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.
Naoi M; Maruyama W
Curr Pharm Des; 2010; 16(25):2799-817. PubMed ID: 20698822
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic strategy for Parkinson's and Alzheimer's disease.
Esposito E; Cuzzocrea S
Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718
[TBL] [Abstract][Full Text] [Related]
9. A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-β aggregation and Ca(2+) dyshomeostasis.
León R; Marco-Contelles J
Curr Med Chem; 2011; 18(4):552-76. PubMed ID: 21143111
[TBL] [Abstract][Full Text] [Related]
10. Metal attenuating therapies in neurodegenerative disease.
Mot AI; Wedd AG; Sinclair L; Brown DR; Collins SJ; Brazier MW
Expert Rev Neurother; 2011 Dec; 11(12):1717-45. PubMed ID: 22091597
[TBL] [Abstract][Full Text] [Related]
11. From stroke to neurodegenerative diseases: The multi-target neuroprotective effects of 3-n-butylphthalide and its derivatives.
Huang L; Wang S; Ma F; Zhang Y; Peng Y; Xing C; Feng Y; Wang X; Peng Y
Pharmacol Res; 2018 Sep; 135():201-211. PubMed ID: 30103000
[TBL] [Abstract][Full Text] [Related]
12. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
Youdim MB; Amit T; Bar-Am O; Weinreb O; Yogev-Falach M
Neurotox Res; 2006 Dec; 10(3-4):181-92. PubMed ID: 17197368
[TBL] [Abstract][Full Text] [Related]
13. ITH12410/SC058: a new neuroprotective compound with potential in the treatment of Alzheimer's disease.
Romero A; Egea J; González-Muñoz GC; Martín de Saavedra MD; del Barrio L; Rodríguez-Franco MI; Conde S; López MG; Villarroya M; de los Ríos C
ACS Chem Neurosci; 2014 Sep; 5(9):770-5. PubMed ID: 25008046
[TBL] [Abstract][Full Text] [Related]
14. Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease.
Hiremathad A; Keri RS; Esteves AR; Cardoso SM; Chaves S; Santos MA
Eur J Med Chem; 2018 Mar; 148():255-267. PubMed ID: 29466775
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.
Weinreb O; Amit T; Mandel S; Youdim MB
Neurodegener Dis; 2012; 10(1-4):112-5. PubMed ID: 22156453
[TBL] [Abstract][Full Text] [Related]
16. Flavonoids in the Treatment of Alzheimer's and Other Neurodegenerative Diseases.
Airoldi C; La Ferla B; D Orazio G; Ciaramelli C; Palmioli A
Curr Med Chem; 2018; 25(27):3228-3246. PubMed ID: 29424298
[TBL] [Abstract][Full Text] [Related]
17. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases.
Dhib-Jalbut S; Arnold DL; Cleveland DW; Fisher M; Friedlander RM; Mouradian MM; Przedborski S; Trapp BD; Wyss-Coray T; Yong VW
J Neuroimmunol; 2006 Jul; 176(1-2):198-215. PubMed ID: 16983747
[TBL] [Abstract][Full Text] [Related]
18. Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease.
Michalska P; Buendia I; Del Barrio L; Leon R
Curr Top Med Chem; 2017; 17(9):1027-1043. PubMed ID: 27697052
[TBL] [Abstract][Full Text] [Related]
19. An overview on neuroprotective effects of isothiocyanates for the treatment of neurodegenerative diseases.
Giacoppo S; Galuppo M; Montaut S; Iori R; Rollin P; Bramanti P; Mazzon E
Fitoterapia; 2015 Oct; 106():12-21. PubMed ID: 26254971
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of naturally occurring biflavonoids.
Kang SS; Lee JY; Choi YK; Song SS; Kim JS; Jeon SJ; Han YN; Son KH; Han BH
Bioorg Med Chem Lett; 2005 Aug; 15(15):3588-91. PubMed ID: 15978805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
